Trastuzumab is an FDA-approved humanized monoclonal antibody that is routinely used as targeted therapy for the treatment of HER2/neu overexpressing breast cancer in combination with other chemotherapy drugs. The gene discussed is ERBB2; the disease is breast cancer.